In vitro studies with the 18F-fluorobenzoic acid (FB) labeled nanobody (anti-MMR 3.49) showed that it had a high affinity for human MMR (KD = 1.8 nM), while in vivo biodistribution studies showed fast renal clearance and specific retention in the tumor and MMR-expressing tissue. Here, MRC1 is linked to neoplasm.